Treatment with Sotrovimab and Casirivimab/Imdevimab Enhances Serum SARS-CoV-2 S Antibody Levels in Patients Infected with the SARS-CoV-2 Delta, Omicron BA.1, and BA.5 Variants.
Kana FujimotoSatoru MutsuoYuto YasudaSoichi ArasawaNoriyuki TashimaDaisuke IwashimaKen-Ichi TakahashiPublished in: Infectious disease reports (2022)
Treatment with sotrovimab could prevent severe disease in high-risk patients infected with SARS-CoV-2 subvariant BA.5.